Study Finds BMD Can Stand in for Fractures. Will the FDA Agree?
A meta-analysis of osteoporosis drugs showed that change in DXA BMD was a surrogate for fracture risk. If accepted by the FDA, it would ‘really open up the field to a lot of new treatments.’ Medscape Medical News …read more